Fluoxetine: A spectrum of clinical applications and postulates of underlying mechanisms

doi:10.1016/S0149-7634(05)80115-0

Neuroscience & Biobehavioral Reviews

Volume 17, Issue 4, Winter 1993, Pages 385-396

https://doi.org/10.1016/S0149-7634(05)80115-0 Get rights and content

The antidepressant efficacy of fluoxetine in major depression has been briefly reviewed. A brief outline of dose selection, therapeutic onset, and pharmacokinetics of fluoxetine were made. The potential use of the drug in management of various psychiatric conditions has been examined. These include obsessive-compulsive disorder and related variances, anorexia nervosa, bulimia nervosa, Tourette's syndrome, and trichotillomania. The suggested use of fluoxetine in pain relief in certain diabetics, premenstrual syndrome, and migraine headache were assessed. The reports on the use of fluoxetine in panic disorders, paraphilias, and related conditions and in the management of substance abuse, alcoholism, and cocaine abuse, were summarized and elaborated upon. A composite of preliminary reports cited in literature pertinent to the potential of fluoxetine in treatment of abusing injurious behavior, dysthymic disorder, fibrositis, postanoxicaction myoclonus, pathologic jealously, personality disorder, pseudobulbar affect, and social phobia were also reviewed. Fluoxetine pharmacological profile may be extended to cover a relative wide range of application, provided future controlled studies confirm the preliminary data found in the literature.

References (261)

AshbyC. et al.
Alteration of platelet serotonergic mechanisms and monoamine oxidase activity in premenstrual syndrome
Biol. Psychiatry
(1988)
BeasleyC.M. et al.
Fluoxetine: A review of receptor and functional effects and their clinical implications
Psychopharmacology (Berlin)
(1992)
BeasleyC.M. et al.
Fluoxetine: No association with suicidality in obsessive-compulsive disorder
J. Affect. Disord.
(1992)
CarrollM. et al.
Fluoxetine reduces intravenous self-administration in rats
Pharmacol. Biochem. Behav.
(1990)
DargaL.L. et al.
Fluoxetine's effect on weight loss in obese subjects
Am. J. Clin. Nutr.
(1991)
Dumbrille-RossA. et al.
Manipulation of synaptic: Discrepency of effects of serotonin S1 and S2 sites
Life Sci
(1983)
FreemanC.P. et al.
Drug and group treatments for bulimia/bulimia nervosa
J. Psychosom. Res.
(1988)
GellerI.
Effect of para-chlorphenylanin and 5-hydroxytryptophan on alcohol intake in the rat
Pharmacol. Biochem. Behav.
(1973)
GellerI. et al.
Blockade of 5-HTP reduction of ethanol drinking with the decarboxylase inhibitor, RO4-4602
Pharmacol. Biochem. Behav.
(1981)
GellerS.A.
Treatment of fibrositis with fluoxetine hydrochloride (Prozac)
Am. J. Med.
(1989)

Gomez-PerezF.H. et al.

Nortriptyline and fluphenazine in the symptomatic treatment of diabetic neuropathy: A double blind cross-over study

Pain

(1985)

GwirtsmanH.E. et al.

Pharmacologic treatment of eating disorder

Psychiatr. Clin. N. Am.

(1984)

HendrenR.L.

Depression in anorexia nervosa

J. Am. Acad. Child Psychiatry

(1983)

HorngJ.S. et al.

Effects of serotonin uptake inhibitor, Lilly 110140, on transport of serotonin in rat and human blood platelets

Biochem. Pharmacol.

(1976)

HsuL.K. et al.

Outcome of anorexia nervosa

Lancet

(1979)

HudsonJ.I. et al.

Phenomenologic relationship of eating disorder to major affective disorder

Psychiatr. Res.

(1983)

AdleyC. et al.

Fluoxetine prophylaxis of migraine

Headache

(1992)

AlexanderR.C.

Fluoxetine treatment of trichotillomania

J. Clin. Psychiatry

(1991)

AltamuraA.C. et al.

The evidence for 20 mg a day fluoxetine as the optimal dose in the treatment of depression

Br. J. Psychiatry

(1988)

Diagnostic and statistical manual of mental disorders

(1987)

AronoffG.R. et al.

Fluoxetine kinetics and protein binding in normal and impaired renal function

Clin. Pharmacol. Ther.

(1984)

BartholiniG. et al.

Decrease of cerebral 5-hydroxytryptamine by 3,4-dihydroxyphenyalamine after inhibition of extracerebral decarboxylase

J. Pharm. Pharmacol.

(1968)

BatkiS.L.

Fluoxetine for cocaine abuse in methadone patients: Preliminary findings

NIDA Res. Monogr.

(1991)

BeasleyC.M. et al.

Fluoxetine: Relationships among dose, response, adverse events and plasma concentrations in the treatment of depression

Psychopharmacol. Bull.

(1990)

BeasleyC.M. et al.

Fluoxetine and suicide: A meta-analysis of controlled trials of treatment for depression

Br. Med. J.

(1991)

BeasleyC.M. et al.

Fluoxetine and suicide: A meta-analysis of controlled trials of treatment of depression

Br. Med. J.

(1991)

BenfieldP. et al.

Fluoxetine: A review of its pharmacodynamic, pharmacokinetic properties and therapeutic efficacy in depressive illness

Drugs

(1986)

BergstromR.F. et al.

Clinical pharmacology and Pharmacokinetics of fluoxetine: A review

Br. J. Psychiatry

(1988)

BergstromR.F. et al.

Fluoxetine steady state pharmacokinetics in depressed patients

Abstracts of the American Pharmaceutical Association Academy of Pharmaceutical Sciences

(1986)

BianchiM.D.

Fluoxetine treatment of exhibitionism

Am. J. Psychiatry

(1990)

BlundellJ.E.

Serotonin and appetite

Neuropharmacology

(1984)

BorisonR.L. et al.

Trazodone and Tourette's syndrome

Neurology

(1983)

BostR.O. et al.

A possible association between fluoxetine use and suicide

J. Anal. Toxicol.

(1992)

BouchardR.H. et al.

Fluoxetine and extrapyramidal side effects

Am. J. Psychiatry

(1989)

BoyerW.F. et al.

An overview of fluoxetine, a new serotonin-specific antidepressant

Mt. Sinai Med. J.

(1989)

BradyK. et al.

Fluoxetine in panic disorder patients with imipramine-associated weight gain

J. Clin. Psychopharmacol.

(1989)

BrasseurR.

A multicenter open trial of fluoxetine in depressed out-patients in Belgium

Int. J. Clin. Psychopharmacol.

(1989)

BremnerJ.D.

Fluoxetine in depressed patients: A comparison with imipramine

J. Clin. Psychiatry

(1984)

BuckleyW.E. et al.

Estimated prevalence of anabolic steroid use among male high school seniors

JAMA

(1988)

CainJ.W.

Poor response to fluoxetine: Underlying depression, serotonergic overstimulation, or a “therapeutic window”

J. Clin. Psychiatry

(1992)

CapriniG. et al.

Un grave sindrome ticcosa guarita Con haloperidol Riv

Sper. Freniat

(1961)

ChouinardG.

A double-blind controlled trial of fluoxetine and amitriptyline of out-patients with major depressive disorders

J. Clin. Psychiatry

(1985)

ChristensonG.A. et al.

A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania

Am. J. Psychiatry

(1991)

ChristensonG.A. et al.

Estimated life-time prevalence of trichotillomania in College students

J. Clin. Psychiatry

(1991)

CoccaroE.F. et al.

Fluoxetine treatment of impulsive aggression in DSM-III-R personality disorder patients

J. Clin. Psychopharmacol.

(1990)

CohnJ.B. et al.

A comparison of fluoxetine, imipramine and placebo in patients with major depressive disorder

J. Clin. Psychiatry

(1985)

ComoP.G. et al.

An open-label trial of fluoxetine for obsessive-compulsive disorder in Gilles de la Tourette's syndrome

Neurology

(1991)

CoppenA. et al.

Abnormalities of indole amines in affective disorders

Arch. Gen. Psychiatry

(1978)

CooperG.L.

The safety of fluoxetine: An update

Br. J. Psychiatry

(1988)

DaamenM.J. et al.

Single-dose fluoxetine in management of premenstrual syndrome

J. Clin. Psychiatry

(1992)

Cited by (34)

Fluoxetine chronic exposure affects growth, behavior and tissue structure of zebrafish
2020, Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology
Citation Excerpt :
Fluoxetine (FLX) is the most prescribed antidepressant worldwide (Richendrfer and Creton, 2017). It acts as a selective inhibitor of 5-hydroxytryptamine (5-HT, serotonin) reuptake, safeguarding the levels of this neurotransmitter in the synaptic cleft (Brooks et al., 2003; Messiha, 1993; Pei et al., 2016; Winder et al., 2011). FLX is prescribed to several mental disorders including major depressive disorder, obsessive-compulsive disorder, nervous bulimia, panic disorder and premenstrual dysphoric disorder (Turner et al., 1985; Wong et al., 2005).
Fluoxetine (FLX) is among the top 100 pharmaceutical prescribed annually worldwide and consequently is often detected in wastewater treatment plant effluent and surface waters, in concentrations up to 2.7 and 0.33 μg/L, respectively. Despite the presence of FLX in surface waters, little is known about its chronic effects in fish. Thus, this study aimed at investigating the chronic toxicity of FLX to Danio rerio adults. Rate of weight gain, behavior (feeding and swimming activity) and tissue organization (liver and intestine) were evaluated, after 30 days exposure. A lower rate of weight gain was observed at 100 μg/L FLX. The food intake time decreased, showing a decrease in fish appetite. The preference for the upper aquarium layer was observed at 10 and 100 μg/L of FLX, indicating an inhibition of the stress level (anxiolytic effect). Mild to moderate damage of hepatic tissue and a decrease epithelium height and increase in villus height of intestine were observed in fish exposed to concentrations as low as 0.01 μg/L. Based on obtained results, chronic exposure of fish to FLX could affect swimming and feeding behavior and alter morphological structure of liver and intestine tissues at environmental levels.
The comorbidity of alcohol dependence and affective disorders: Treatment implications
1998, Drug and Alcohol Dependence
This paper reviews recent literature on the prevalence of alcohol dependence and affective disorders (major depression, dysthymia), the comorbidity of these conditions and the effects of comorbid affective disorders on the outcome of treatment for alcohol dependence. Alcohol dependence and affective disorders co-occur at significantly higher rates than would be expected by chance within the general population. This comorbidity is further elevated in samples of people seeking treatment for alcohol dependence, suggesting that the co-occurrence of affective disorders may be an important determinant of treatment seeking. The results of a number of recent placebo-controlled studies have suggested that pharmacological treatment with anti-depressants may enhance the efficacy of treatment for alcohol dependence in individuals with comorbid affective disorders.
Out of control: Visceral influences on behavior
1996, Organizational Behavior and Human Decision Processes
Understanding discrepancies between behavior and perceived self-interest has been one of the major, but largely untackled, theoretical challenges confronting decision theory from its infancy to the present. People often act against their self-interest in full knowledge that they are doing so; they experience a feeling of being “out of control.” This paper attributes this phenomenon to the operation of “visceral factors,” which include drive states such as hunger, thirst and sexual desire, moods and emotions, physical pain, and craving for a drug one is addicted to. The defining characteristics of visceral factors are, first, a direct hedonic impact (which is usually negative), and second, an effect on the relative desirability of different goods and actions. The largely aversive experience of hunger, for example, affects the desirability of eating, but also of other activities such as sex. Likewise, fear and pain are both aversive, and both increase the desirability of withdrawal behaviors. The visceral factor perspective has two central premises: First, immediately experienced visceral factors have a disproportionate effect on behavior and tend to “crowd out” virtually all goals other than that of mitigating the visceral factor. Second, people underweigh, or even ignore, visceral factors that they will experience in the future, have experienced in the past, or that are experienced by other people. The paper details these two assumptions, then shows how they can help to explain a wide range of phenomena: impulsivity and self-control, drug addiction, various anomalies concerning sexual behavior, the effect of vividness on decision making, and certain phenomena relating to motivation and action.
Tricyclic antidepressants and selective serotonin reuptake inhibitors but not anticonvulsants ameliorate pain, anxiety, and depression symptoms in an animal model of central post-stroke pain
2021, Molecular Pain
Chronic Fluoxetine Impairs the Effects of 5-HT<inf>1A</inf> and 5-HT<inf>2C</inf> Receptors Activation in the PAG and Amygdala on Antinociception Induced by Aversive Situation in Mice
2020, Frontiers in Pharmacology
NueDexta: A treatment for pseudobulbar affect
2015, Issues in Mental Health Nursing

View all citing articles on Scopus

View full text

Fluoxetine: A spectrum of clinical applications and postulates of underlying mechanisms

Biol. Psychiatry

Psychopharmacology (Berlin)

J. Affect. Disord.

Pharmacol. Biochem. Behav.

Am. J. Clin. Nutr.

Life Sci

J. Psychosom. Res.

Pharmacol. Biochem. Behav.

Pharmacol. Biochem. Behav.

Am. J. Med.

Pain

Psychiatr. Clin. N. Am.

J. Am. Acad. Child Psychiatry

Biochem. Pharmacol.

Lancet

Psychiatr. Res.

Fluoxetine prophylaxis of migraine

Headache

Fluoxetine treatment of trichotillomania

J. Clin. Psychiatry

The evidence for 20 mg a day fluoxetine as the optimal dose in the treatment of depression

Br. J. Psychiatry

Diagnostic and statistical manual of mental disorders

Fluoxetine kinetics and protein binding in normal and impaired renal function

Clin. Pharmacol. Ther.

Decrease of cerebral 5-hydroxytryptamine by 3,4-dihydroxyphenyalamine after inhibition of extracerebral decarboxylase

J. Pharm. Pharmacol.

Fluoxetine for cocaine abuse in methadone patients: Preliminary findings

NIDA Res. Monogr.

Fluoxetine: Relationships among dose, response, adverse events and plasma concentrations in the treatment of depression

Psychopharmacol. Bull.

Fluoxetine and suicide: A meta-analysis of controlled trials of treatment for depression

Br. Med. J.

Fluoxetine and suicide: A meta-analysis of controlled trials of treatment of depression

Br. Med. J.

Fluoxetine: A review of its pharmacodynamic, pharmacokinetic properties and therapeutic efficacy in depressive illness

Drugs

Clinical pharmacology and Pharmacokinetics of fluoxetine: A review

Br. J. Psychiatry

Fluoxetine steady state pharmacokinetics in depressed patients

Abstracts of the American Pharmaceutical Association Academy of Pharmaceutical Sciences

Fluoxetine treatment of exhibitionism

Am. J. Psychiatry

Serotonin and appetite

Neuropharmacology

Trazodone and Tourette's syndrome

Neurology

A possible association between fluoxetine use and suicide

J. Anal. Toxicol.

Fluoxetine and extrapyramidal side effects

Am. J. Psychiatry

An overview of fluoxetine, a new serotonin-specific antidepressant

Mt. Sinai Med. J.

Fluoxetine in panic disorder patients with imipramine-associated weight gain

J. Clin. Psychopharmacol.

A multicenter open trial of fluoxetine in depressed out-patients in Belgium

Int. J. Clin. Psychopharmacol.

Fluoxetine in depressed patients: A comparison with imipramine

J. Clin. Psychiatry

Estimated prevalence of anabolic steroid use among male high school seniors

JAMA

Poor response to fluoxetine: Underlying depression, serotonergic overstimulation, or a “therapeutic window”

J. Clin. Psychiatry

Un grave sindrome ticcosa guarita Con haloperidol Riv

Sper. Freniat

A double-blind controlled trial of fluoxetine and amitriptyline of out-patients with major depressive disorders

J. Clin. Psychiatry

A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania

Am. J. Psychiatry

Estimated life-time prevalence of trichotillomania in College students

J. Clin. Psychiatry

Fluoxetine treatment of impulsive aggression in DSM-III-R personality disorder patients

J. Clin. Psychopharmacol.

A comparison of fluoxetine, imipramine and placebo in patients with major depressive disorder

J. Clin. Psychiatry

An open-label trial of fluoxetine for obsessive-compulsive disorder in Gilles de la Tourette's syndrome

Neurology

Abnormalities of indole amines in affective disorders

Arch. Gen. Psychiatry